The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, and precision oncology technologies. North America leads the market with 41.2% share, supported by strong healthcare infrastructure and research funding. Blood tests and hospital laboratories are key segments, with Asia-Pacific expected to show the highest growth due to rising cancer incidence and healthcare investments.
A $2 million investment portfolio can generate a six-figure income without the risks and maintenance of rental properties by focusing on dividend-paying stocks and funds. Conservative portfolios yield 3% to 4%, offering steady growth but lower initia...
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides a more reliable and growing dividend income by holding companies with at least 25 years of consecutive dividend increases, unlike the SPDR S&P 500 ETF (SPY), which includes all S&P 500 co...
